If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Hydrolysis === DBNPA undergoes rapid pH-dependent hydrolysis in aqueous environments, leading to the formation of different degradation products. The C-Br bonds break down rapidly into smaller organic and inorganic byproducts when exposed to neutral to alkaline environments due to nucleophilic substitution. DBNPA can endure longer in acidic settings since the hydrolysis rate is lower. The pH has a significant impact on DBNPA's breakdown. The main degradation product at pH 5 is dibromoacetic acid (DBAA), which makes up 30.6% of all DBNPA breakdown products. The breakdown mechanism changes as the pH rises, favouring the synthesis of dibromoacetonitrile (DBAN), which dominates at pH 7 (54.5%) and pH 9 (38.6%). Ammonia, carbon dioxide, bromide ions, and cyanoacetic acid are produced by further hydrolysis in neutral or slightly alkaline conditions.
"Clinical evaluation of De Marco formula as an adjunctive therapy for infected ischemic diabetic foot: a prospective randomized controlled trial". Can J Clin Pharmacol. 16 (2): e381–91. PMID 19966380. DeMarco Peter. "Treatment of Macular Degeneration." United States Patent Application, US 20040180090.
== Taxonomy == German naturalist Wilhelm Peters described the coastal taipan as Pseudechis scutellatus in 1867, from material collected in Rockhampton, Queensland. Charles Walter De Vis described Pseudechis wilesmithii from Walsh River in north Queensland in 1911. In 1922, scientific bird collector William McLennan killed two snakes near Coen in far north Queensland. Impressed by their size—up to 2.76 m, he sent the skins and skulls to the Australian Museum in Sydney. Australian naturalist Roy Kinghorn established the genus Oxyuranus in 1923, describing a specimen from Coen as O. maclennani after its collector. He noted the distinctness of the palatine bone necessitated the new genus as distinct from all other elapid snakes. In 1930, Kinghorn announced it as the second largest venomous snake in the world, with 3/4 inch fangs. In 1933, Australian zoologist Donald Thomson concluded that Pseudechis scutellatus and Oxyuranus maclennani were the same species; this meant that Peters' specific epithet had priority, as did Kinghorn's genus as the species was highly distinct. Hence, the coastal taipan became Oxyuranus scutellatus. Thomson had spent some years in Cape York peninsula with the indigenous people, who told tales of a giant snake they greatly feared. Australian herpetologist Ken Slater described Oxyuranus scutellatus canni, commonly known as the Papuan taipan, in 1956, on the basis of its distinctive coloration. He named it after George Cann, longtime Snake Man of La Perouse. It is found throughout the southern portion of the island of New Guinea.
== See also == Rec. 2020 – ITU-R Recommendation for UHDTV 4K resolution – Resolutions of common 4K formats and list of 4K-monitors, TVs, projectors 8K resolution – Specifications for ~8x4K UHD and 8Kx8K fulldome Ultra HD Blu-ray – 2160p / 4K (3840 × 2160 resolution) format Blu-ray Disc as specified by Blu-ray Disc Association IMAX – A film theater format that historically has been innovative in creating a more realistic viewing experience High Efficiency Video Coding (HEVC) VP9 / WebM 22.2 surround sound – The audio component of Super Hi-Vision
In the classical pathway, C1 complex recognizes two IgGs or one pentamer IgM, forming an antigen-antibody complex. For the lectin pathway, mannose-binding lectin (MBL) and their associated serine proteins (MASPs), recognize carbohydrates on pathogens, which initiates the C3 convertase C4b2b. The alternative pathway is different due to its spontaneous activation in fluid phase by hydrolysis of C3 to C3(H2O). C3(H2O) can bind to Factor B, which can then be cleaved by the serum protease Factor D, resulting in formation of C3(H2O)Bb. C3(H2O)Bb can cleave additional C3 molecules, creating C3b and C3a.
Sources: en.wikipedia.org
=== Made by Nacho === In April 2021, Flay, with Elly Truesdell and Katja Lang, launched Made by Nacho, a premium cat food company named for his Maine Coon, Nacho Flay. The brand sells wet cat food, dry kibble, and freeze-dried protein treats. Made by Nacho sells cat food from their website and in PetSmart in addition to offering a subscription service. Flay has also founded the Made By Nacho Charitable Fund as part of The New York Community Trust.
=== Commercial === Commercial availability varies by country. Approved systems in various countries, described further below, include MiniMed 670G or 780G, Tandem's Control-IQ, Omnipod 5, CamAPS FX, and Diabeloop DBLG1.
After experiencing patella tendinitis in his knee during 2016, Hibberd was eased back into pre-season training. In addition to sustaining a hamstring injury which limited his training further and he was forced to miss the opening match of the 2017 JLT Community Series. He played his first match in Melbourne colours in Melbourne's second match of the JLT Community Series, which was a fifty-four point win against Carlton at Casey Fields. A few days later, he suffered an achilles injury at training, which forced him to miss five weeks of football. He returned to playing via the VFL with Melbourne's affiliate team, the Casey, in the round one clash against Williamstown at Burbank Oval, in which he recorded twenty-five disposals and was one of Casey's best players according to elite performance manager, Dave Misson. He spent just the one week in the VFL before making his debut for Melbourne in the Anzac Day eve match against Richmond at the Melbourne Cricket Ground in round five where he recorded twenty-seven disposals, eight rebound 50s, six marks and a goal. He was named Melbourne's best player by Herald Sun journalist, Sam Landsberger, and was named in AFL Media's team of the week. He played every match for the remainder of the season to finish with eighteen games and averaged career-highs in disposals (27.4) and rebound 50s (6.8), the latter of which ranked second in the league; furthermore he averaged the highest metres gained per match (545.7) in the league.
This relation has the correct behavior at extreme values of R∗, as shown by the labeled curve in Figure 3: when R∗ is small, it is consistent with smooth pipe flow, when large, it is consistent with rough pipe flow. However its performance in the transitional domain overestimates the friction factor by a substantial margin. Colebrook acknowledges the discrepancy with Nikuradze's data but argues that his relation is consistent with the measurements on commercial pipes. Indeed, such pipes are very different from those carefully prepared by Nikuradse: their surfaces are characterized by many different roughness heights and random spatial distribution of roughness points, while those of Nikuradse have surfaces with uniform roughness height, with the points extremely closely packed.
Sources: en.wikipedia.org
=== Standard addition === The method of standard addition is used in instrumental analysis to determine the concentration of a substance (analyte) in an unknown sample by comparison to a set of samples of known concentration, similar to using a calibration curve. Standard addition can be applied to most analytical techniques and is used instead of a calibration curve to solve the matrix effect problem.
The reduction of activation energy (Ea) increases the fraction of reactant molecules that can overcome this barrier and form the product. An important principle is that since they only reduce energy barriers between products and reactants, enzymes always catalyze reactions in both directions, and cannot drive a reaction forward or affect the equilibrium position – only the speed with which is it achieved. As with other catalysts, the enzyme is not consumed or changed by the reaction (as a substrate is) but is recycled such that a single enzyme performs many rounds of catalysis. Enzymes are often highly specific, i.e. they only act on particular substrates, sometimes only one. Others show group specificity and can act on similar but not identical chemical groups such as peptide bonds. Many enzymes have stereochemical specificity and act on one stereoisomer but not another.
=== Full scan MS === When collecting data in the full scan mode, a target range of mass fragments is determined and put into the instrument's method. An example of a typical broad range of mass fragments to monitor would be m/z 50 to m/z 400. The determination of what range to use is largely dictated by what one anticipates being in the sample while being cognizant of the solvent and other possible interferences. A MS should not be set to look for mass fragments too low or else one may detect air (found as m/z 28 due to nitrogen), carbon dioxide (m/z 44) or other possible interference. Additionally if one is to use a large scan range then sensitivity of the instrument is decreased due to performing fewer scans per second since each scan will have to detect a wide range of mass fragments. Full scan is useful in determining unknown compounds in a sample. It provides more information than SIM when it comes to confirming or resolving compounds in a sample. During instrument method development it may be common to first analyze test solutions in full scan mode to determine the retention time and the mass fragment fingerprint before moving to a SIM instrument method.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.